证券日报网讯2月25日，迪安诊断（300244）在互动平台回答投资者提问时表示，公司于2025年制定了 AI三年战略规划，致力于将AI技术从辅助手段升级为驱动业务增长的核心引擎，尤其在疾病风险评 估、健康管理、专病辅助诊断等场景中创造新业务价值。公司正沿着AI+CDSS(辅助临床决策)、AI+健 康管理、AI+CRO、数据产品四大方向稳步推进，实现从技术研发到商业落地的无缝衔接。医疗AI业务 尚处于投入阶段，二级市场股价受宏观经济、行业动态、投资者预期等多重因素影响，敬请注意投资风 险。 ...

Core Viewpoint - 美中嘉和 (02453.HK) has entered into a placement agreement with Guotai Junan International to issue 48.72 million shares at a price of HKD 5.54 per share, representing approximately 18.38% of the existing H shares and 6.63% of the total issued shares as of the announcement date [1][2] Group 1: Placement Details - The placement involves 48.72 million shares, which will be issued under a general authorization [1] - The placement shares will account for approximately 15.52% of the enlarged issued H shares and about 6.22% of the total issued shares after the placement [1] Group 2: Use of Proceeds - The total expected proceeds from the placement are approximately HKD 270 million, with a net amount of about HKD 259 million [2] - The net proceeds will be allocated as follows: - Approximately HKD 77.63 million (30%) for the construction of Shanghai Taihe Cheng Tumor Hospital, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 38.82 million (15%) to support the company's medical AI business, including operational and R&D expenses, also expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 64.69 million (25%) for repaying loans from financial institutions, including principal and interest for working capital loans and fixed asset loans, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 77.63 million (30%) for replenishing the company's working capital and general corporate purposes, expected to be fully utilized by June 30, 2026 [2]